ArticleFish physiology and biochemistry2026
Effects of dietary supplementation with the antimicrobial peptide Sublancin on growth performance, antioxidant capacity, intestinal health, immune performance, and resistance to Aeromonas hydrophila in juvenile largemouth bass (Micropterus salmoides).
Article in Fish physiology and biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 56-day feeding trial was carried out to investigate how dietary Sublancin affects growth performance, antioxidative status, immune function, gut health, and disease resistance in largemouth bass. Five isonitrogenous and isocaloric experimental diets containing Sublancin at concentrations of 0 (Control), 100, 200, 400, and 800 mg/kg were formulated, which were respectively named Control, Sublancin 100, Sublancin 200, Sublancin 400, and Sublancin 800. Compared with the Control, the Sublancin 400 exhibited greater final body weight, weight gain rate, and specific growth rate (P < 0.05). The condition factor was higher in the Sublancin 200, 400, and 800 (P < 0.05). Across all Sublancin supplemented groups, serum total protein and albumin levels rose prominently (P < 0.05). Villus height (VH) and muscle thickness (MT) increased notably in the Sublancin 200 (P < 0.05), whereas villus width (VW) showed remarkable elevation in the Sublancin 400 (P < 0.05). The activities of superoxide dismutase (SOD), total antioxidant capacity (T-AOC), and catalase (CAT) were higher in the Sublancin 400 (P < 0.05). Transcript levels of occludin and claudin C were upregulated in the Sublancin 400 and Sublancin 800 (P < 0.05). The anti-inflammatory cytokines il-10 and tgf-β exhibited notable increases, while the pro-inflammatory cytokines il-8, tnf-α, and il-1β decreased in the Sublancin 400 (P < 0.05). After challenge with Aeromonas hydrophila, no deaths occurred in the Sublancin 200-400; however, mortality was observed in the other groups. In summary, Sublancin at 200-400 mg/kg improved growth performance, antioxidative status, intestinal barrier integrity, and post-challenge survival rate in largemouth bass. These findings provide a theoretical basis for incorporating Sublancin into aquaculture feeds.
Indexed as
Identifiers
42848103What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.